Facebook Pixel TECH-POWERED WAR ON AMR | BioSpectrum Asia - business - Bu hikayeyi Magzter.com'da okuyun

Denemek ALTIN - Özgür

TECH-POWERED WAR ON AMR

BioSpectrum Asia

|

July 2023

The consistent increase in antimicrobial resistance (AMR) is threatening to undo many of the gains of modern medicine. The situation is particularly alarming in the Asia Pacific region, which could witness around 50 per cent of global annual AMR-related mortality by 2050. Around 62 per cent of antibiotics in the region are used without prescriptions, indicating inappropriate usage and significantly increasing the risk of AMR strain emergence, according to a report from LEK Consulting Group. All this makes the region an epicentre of AMR and its consequences. In response to the growing threat, countries in the region have taken steps to tackle the AMR threat. These include a National Action Plan on AMR (NAP-AMR), antimicrobial stewardship efforts, diagnostics surveillance etc. However, the million-dollar question is whether these steps will be effective and enough. Let’s find out.

- Ayesha Siddiqui

TECH-POWERED WAR ON AMR

I 'n 2022, the World Health Organisation SouthEast Asia Region (WHO SEAR) released the third progress analysis of implementing NAPS to address AMR. The analysis reveals that all eleven member states in the region made progress against the NAP-AMR between 2018 and 2021, with Bhutan, Korea, and Thailand leading the way. These achievements occurred despite the challenges posed by the COVID-19 pandemic. The implementation of NAP-AMR in all countries of the region reached 64 per cent progress, a significant improvement compared to 40 per cent recorded in the second situational analysis in 2018. Furthermore, there were no reported regressions in implementation status during 2021, as compared to the 2018 analysis. Many innovative approaches and technologies are being deployed against the AMR scourge.

There have been incremental steps taken to address this monumental crisis. Experts, however, believe that the progress made so far is not enough given the severity of the situation.

Sharing his views on the steps taken John Alter, Head of external affairs at the AMR Action Fund

BioSpectrum Asia'den DAHA FAZLA HİKAYE

BioSpectrum Asia

BioSpectrum Asia

Alphamab Oncology appoints Fei Wang as Chief Financial Officer

Hong Kong-based Alphamab Oncology has announced the appointment of Fei Wang as the Chief Financial Officer (CFO).

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

BioSpectrum Asia

CarbGeM inks MoU with DSS Imagetech to expand AI business in Indian market

DSS Imagetech, a leading player in medical and research imaging equipment, has announced the signing of a Memorandum of Understanding (MoU) with Japan-based CarbGeM Inc., a developer of artificial intelligence (AI)-powered life science solutions to expand its AI business in the Indian market.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

BioSpectrum Asia

PHCbi introduces LiCellGrow Cell Expansion System

PHC Corporation's Biomedical Division, a global provider of laboratory sample storage and cell cultivation solutions and subsidiary of Japan's PHC Holdings Corporation, has announced the launch of its new cell expansion system LiCellGrow for research use in Japan and other select countries worldwide.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

BioSpectrum Asia

CitiusTech appoints Dhaval Shah as Chief Business Officer - MedTech & Life Sciences

CitiusTech, a leading provider of healthcare technology services driving digital and AI excellence in India, has appointed Dhaval Shah to Chief Business Officer - MedTech & Life Sciences.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

Thermo Fisher expands immunodiagnostics operations with new distribution centre in Uppsala

Thermo Fisher Scientific Inc. has announced the opening of a new 8,000-square-meter distribution & labeling centre supporting its immunodiagnostics business in Uppsala.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

BioSpectrum Asia

Harbour BioMed appoints Dr Jenny Xie as Head of Global External Innovation

Harbour BioMed, a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, has announced the appointment of Dr Jenny Xie as Chief Scientific Officer, Immunology and Head of Global External Innovation.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

BioSpectrum Asia

Argo Biopharma ropes in Dr Gena Wang as CFO and CSO

China-based Argo Biopharmaceutical Co., a clinical-stage biotechnology company committed to developing next-generation siRNA therapies, has announced the appointment of Dr Gena Wang as Chief Financial Officer (CFO) and Chief Strategy Officer (CSO), effective March 1, 2026.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

IISc launches "Moonshot" project on brain co-processors supported by Pratiksha Trust

The Indian Institute of Science (IISc), Bengaluru has launched an ambitious \"moonshot\" project to develop brain co-processors that combine neuromorphic hardware and artificial intelligence (AI) algorithms to enhance or restore brain function.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

Korea designs model for accurate and scalable drug-drug interaction prediction

A research team from the School of International Engineering and Science at Jeonbuk National University (JBNU), South Korea, has developed DDINet, a lightweight and scalable model, specifically designed to predict interactions for new, unseen drugs.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

BioSpectrum Asia

Australia-Singapore study advocates role of intranasal vaccine booster against sarbecoviruses

Researchers at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) and Monash University in Australia, have demonstrated that an intranasal vaccine booster may confer significantly stronger and broader immune responses, and provide robust neutralising antibody and resident T cell responses in the lung and nasal tissues, outperforming conventional mRNA booster vaccination.

time to read

1 min

BioSpectrum Asia April 2027

Translate

Share

-
+

Change font size